603 results on '"Jacquemin, E."'
Search Results
2. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA
- Author
-
Hansen, B, Vandriel, S, Vig, P, Garner, W, Mogul, D, Loomes, K, Piccoli, D, Rand, E, Jankowska, I, Czubkowski, P, Gliwicz-Miedzinska, D, Gonzales, E, Jacquemin, E, Bouligand, J, D'Antiga, L, Nicastro, E, Arnell, H, Fischler, B, Sokal, E, Demaret, T, Siew, S, Stormon, M, Karpen, S, Romero, R, Ebel, N, Feinstein, J, Roberts, A, Evans, H, Sundaram, S, Chaidez, A, Hardikar, W, Shankar, S, Fischer, R, Lacaille, F, Debray, D, Lin, H, Jensen, M, Jaramillo, C, Karthikeyan, P, Indolfi, G, Verkade, H, Larson-Nath, C, Quiros-Tejeira, R, Valentino, P, Rogalidou, M, Dezsofi, A, Squires, J, Schwarz, K, Calvo, P, Bernabeu, J, Zizzo, A, Nebbia, G, Bulut, P, Santos-Silva, E, Fawaz, R, Nastasio, S, Karnsakul, W, Tamara, M, Busoms, C, Kelly, D, Sandahl, T, Jimenez-Rivera, C, Banales, J, Mujawar, Q, Li, L, She, H, Wang, J, Kim, K, Oh, S, Sanchez, M, Cavalieri, M, Lee, W, Hajinicolaou, C, Lertudomphonwanit, C, Waisbourd-Zinman, O, Arikan, C, Alam, S, Carvalho, E, Melere, M, Eshun, J, Onal, Z, Desai, D, Wiecek, S, Pinto, R, Wolters, V, Garcia, J, Beretta, M, Kerkar, N, Brecelj, J, Rock, N, Lurz, E, Blondet, N, Shah, U, Thompson, R, Kamath, B, Hansen B. E., Vandriel S. M., Vig P., Garner W., Mogul D. B., Loomes K. M., Piccoli D. A., Rand E. B., Jankowska I., Czubkowski P., Gliwicz-Miedzinska D., Gonzales E. M., Jacquemin E., Bouligand J., D'Antiga L., Nicastro E., Arnell H., Fischler B., Sokal E., Demaret T., Siew S., Stormon M., Karpen S. J., Romero R., Ebel N. H., Feinstein J. A., Roberts A. J., Evans H. M., Sundaram S. S., Chaidez A., Hardikar W., Shankar S., Fischer R. T., Lacaille F., Debray D., Lin H. C., Jensen M. K., Jaramillo C., Karthikeyan P., Indolfi G., Verkade H. J., Larson-Nath C., Quiros-Tejeira R. E., Valentino P. L., Rogalidou M., Dezsofi A., Squires J. E., Schwarz K., Calvo P. L., Bernabeu J. Q., Zizzo A. N., Nebbia G., Bulut P., Santos-Silva E., Fawaz R., Nastasio S., Karnsakul W., Tamara M. L., Busoms C. M., Kelly D. A., Sandahl T. D., Jimenez-Rivera C., Banales J. M., Mujawar Q., Li L. -T., She H., Wang J. -S., Kim K. M., Oh S. H., Sanchez M. C., Cavalieri M. L., Lee W. S., Hajinicolaou C., Lertudomphonwanit C., Waisbourd-Zinman O., Arikan C., Alam S., Carvalho E., Melere M., Eshun J., Onal Z., Desai D. M., Wiecek S., Pinto R. B., Wolters V. M., Garcia J., Beretta M., Kerkar N., Brecelj J., Rock N., Lurz E., Blondet N., Shah U., Thompson R. J., Kamath B. M., Hansen, B, Vandriel, S, Vig, P, Garner, W, Mogul, D, Loomes, K, Piccoli, D, Rand, E, Jankowska, I, Czubkowski, P, Gliwicz-Miedzinska, D, Gonzales, E, Jacquemin, E, Bouligand, J, D'Antiga, L, Nicastro, E, Arnell, H, Fischler, B, Sokal, E, Demaret, T, Siew, S, Stormon, M, Karpen, S, Romero, R, Ebel, N, Feinstein, J, Roberts, A, Evans, H, Sundaram, S, Chaidez, A, Hardikar, W, Shankar, S, Fischer, R, Lacaille, F, Debray, D, Lin, H, Jensen, M, Jaramillo, C, Karthikeyan, P, Indolfi, G, Verkade, H, Larson-Nath, C, Quiros-Tejeira, R, Valentino, P, Rogalidou, M, Dezsofi, A, Squires, J, Schwarz, K, Calvo, P, Bernabeu, J, Zizzo, A, Nebbia, G, Bulut, P, Santos-Silva, E, Fawaz, R, Nastasio, S, Karnsakul, W, Tamara, M, Busoms, C, Kelly, D, Sandahl, T, Jimenez-Rivera, C, Banales, J, Mujawar, Q, Li, L, She, H, Wang, J, Kim, K, Oh, S, Sanchez, M, Cavalieri, M, Lee, W, Hajinicolaou, C, Lertudomphonwanit, C, Waisbourd-Zinman, O, Arikan, C, Alam, S, Carvalho, E, Melere, M, Eshun, J, Onal, Z, Desai, D, Wiecek, S, Pinto, R, Wolters, V, Garcia, J, Beretta, M, Kerkar, N, Brecelj, J, Rock, N, Lurz, E, Blondet, N, Shah, U, Thompson, R, Kamath, B, Hansen B. E., Vandriel S. M., Vig P., Garner W., Mogul D. B., Loomes K. M., Piccoli D. A., Rand E. B., Jankowska I., Czubkowski P., Gliwicz-Miedzinska D., Gonzales E. M., Jacquemin E., Bouligand J., D'Antiga L., Nicastro E., Arnell H., Fischler B., Sokal E., Demaret T., Siew S., Stormon M., Karpen S. J., Romero R., Ebel N. H., Feinstein J. A., Roberts A. J., Evans H. M., Sundaram S. S., Chaidez A., Hardikar W., Shankar S., Fischer R. T., Lacaille F., Debray D., Lin H. C., Jensen M. K., Jaramillo C., Karthikeyan P., Indolfi G., Verkade H. J., Larson-Nath C., Quiros-Tejeira R. E., Valentino P. L., Rogalidou M., Dezsofi A., Squires J. E., Schwarz K., Calvo P. L., Bernabeu J. Q., Zizzo A. N., Nebbia G., Bulut P., Santos-Silva E., Fawaz R., Nastasio S., Karnsakul W., Tamara M. L., Busoms C. M., Kelly D. A., Sandahl T. D., Jimenez-Rivera C., Banales J. M., Mujawar Q., Li L. -T., She H., Wang J. -S., Kim K. M., Oh S. H., Sanchez M. C., Cavalieri M. L., Lee W. S., Hajinicolaou C., Lertudomphonwanit C., Waisbourd-Zinman O., Arikan C., Alam S., Carvalho E., Melere M., Eshun J., Onal Z., Desai D. M., Wiecek S., Pinto R. B., Wolters V. M., Garcia J., Beretta M., Kerkar N., Brecelj J., Rock N., Lurz E., Blondet N., Shah U., Thompson R. J., and Kamath B. M.
- Abstract
BACKGROUND AND AIMS: Alagille syndrome (ALGS) is characterized by chronic cholestasis with associated pruritus and extrahepatic anomalies. Maralixibat, an ileal bile acid transporter inhibitor, is an approved pharmacologic therapy for cholestatic pruritus in ALGS. Since long-term placebo-controlled studies are not feasible or ethical in children with rare diseases, a novel approach was taken comparing 6-year outcomes from maralixibat trials with an aligned and harmonized natural history cohort from the G lobal AL agille A lliance (GALA) study. APPROACH AND RESULTS: Maralixibat trials comprise 84 patients with ALGS with up to 6 years of treatment. GALA contains retrospective data from 1438 participants. GALA was filtered to align with key maralixibat eligibility criteria, yielding 469 participants. Serum bile acids could not be included in the GALA filtering criteria as these are not routinely performed in clinical practice. Index time was determined through maximum likelihood estimation in an effort to align the disease severity between the two cohorts with the initiation of maralixibat. Event-free survival, defined as the time to first event of manifestations of portal hypertension (variceal bleeding, ascites requiring therapy), surgical biliary diversion, liver transplant, or death, was analyzed by Cox proportional hazards methods. Sensitivity analyses and adjustments for covariates were applied. Age, total bilirubin, gamma-glutamyl transferase, and alanine aminotransferase were balanced between groups with no statistical differences. Event-free survival in the maralixibat cohort was significantly better than the GALA cohort (HR, 0.305; 95% CI, 0.189-0.491; p <0.0001). Multiple sensitivity and subgroup analyses (including serum bile acid availability) showed similar findings. CONCLUSIONS: This study demonstrates a novel application of a robust statistical method to evaluate outcomes in long-term intervention studies where placebo comparisons are not feasible, p
- Published
- 2024
3. Facteurs de risque et évolution des allergies alimentaires IgE médiées avant et après transplantation hépatique dans une cohorte pédiatrique française
- Author
-
Guiddir, T., Krzysiek, R., Kyheng, C., Cohen, J., Ackermann, O., Jacquemin, E., and Nemni, A.
- Published
- 2022
- Full Text
- View/download PDF
4. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study
- Author
-
Vandriel, S, Li, L, She, H, Wang, J, Gilbert, M, Jankowska, I, Czubkowski, P, Gliwicz-Miedzinska, D, Gonzales, E, Jacquemin, E, Bouligand, J, Spinner, N, Loomes, K, Piccoli, D, D'Antiga, L, Nicastro, E, Sokal, A, Demaret, T, Ebel, N, Feinstein, J, Fawaz, R, Nastasio, S, Lacaille, F, Debray, D, Arnell, H, Fischler, B, Siew, S, Stormon, M, Karpen, S, Romero, R, Kim, K, Baek, W, Hardikar, W, Shankar, S, Roberts, A, Evans, H, Jensen, M, Kavan, M, Sundaram, S, Chaidez, A, Karthikeyan, P, Sanchez, M, Cavalieri, M, Verkade, H, Lee, W, Squires, J, Hajinicolaou, C, Lertudomphonwanit, C, Fischer, R, Larson-Nath, C, Mozer-Glassberg, Y, Arikan, C, Lin, H, Bernabeu, J, Alam, S, Kelly, D, Carvalho, E, Ferreira, C, Indolfi, G, Quiros-Tejeira, R, Bulut, P, Calvo, P, Anal, Z, Valentino, P, Desai, D, Eshun, J, Rogalidou, M, Dezsofi, A, Wiecek, S, Nebbia, G, Pinto, R, Wolters, V, Tamara, M, Zizzo, A, Garcia, J, Schwarz, K, Beretta, M, Sandahl, T, Jimenez-Rivera, C, Kerkar, N, Brecelj, J, Mujawar, Q, Rock, N, Busoms, C, Karnsakul, W, Lurz, E, Santos-Silva, E, Blondet, N, Bujanda, L, Shah, U, Thompson, R, Hansen, B, Kamath, B, Vandriel S. M., Li L. -T., She H., Wang J. -S., Gilbert M. A., Jankowska I., Czubkowski P., Gliwicz-Miedzinska D., Gonzales E. M., Jacquemin E., Bouligand J., Spinner N. B., Loomes K. M., Piccoli D. A., D'Antiga L., Nicastro E., Sokal A., Demaret T., Ebel N. H., Feinstein J. A., Fawaz R., Nastasio S., Lacaille F., Debray D., Arnell H., Fischler B., Siew S., Stormon M., Karpen S. J., Romero R., Kim K. M., Baek W. Y., Hardikar W., Shankar S., Roberts A. J., Evans H. M., Jensen M. K., Kavan M., Sundaram S. S., Chaidez A., Karthikeyan P., Sanchez M. C., Cavalieri M. L., Verkade H. J., Lee W. S., Squires J. E., Hajinicolaou C., Lertudomphonwanit C., Fischer R. T., Larson-Nath C., Mozer-Glassberg Y., Arikan C., Lin H. C., Bernabeu J. Q., Alam S., Kelly D. A., Carvalho E., Ferreira C. T., Indolfi G., Quiros-Tejeira R. E., Bulut P., Calvo P. L., Anal Z., Valentino P. L., Desai D. M., Eshun J., Rogalidou M., Dezsofi A., Wiecek S., Nebbia G., Pinto R. B., Wolters V. M., Tamara M. L., Zizzo A. N., Garcia J., Schwarz K., Beretta M., Sandahl T. D., Jimenez-Rivera C., Kerkar N., Brecelj J., Mujawar Q., Rock N., Busoms C. M., Karnsakul W., Lurz E., Santos-Silva E., Blondet N., Bujanda L., Shah U., Thompson R. J., Hansen B. E., Kamath B. M., Vandriel, S, Li, L, She, H, Wang, J, Gilbert, M, Jankowska, I, Czubkowski, P, Gliwicz-Miedzinska, D, Gonzales, E, Jacquemin, E, Bouligand, J, Spinner, N, Loomes, K, Piccoli, D, D'Antiga, L, Nicastro, E, Sokal, A, Demaret, T, Ebel, N, Feinstein, J, Fawaz, R, Nastasio, S, Lacaille, F, Debray, D, Arnell, H, Fischler, B, Siew, S, Stormon, M, Karpen, S, Romero, R, Kim, K, Baek, W, Hardikar, W, Shankar, S, Roberts, A, Evans, H, Jensen, M, Kavan, M, Sundaram, S, Chaidez, A, Karthikeyan, P, Sanchez, M, Cavalieri, M, Verkade, H, Lee, W, Squires, J, Hajinicolaou, C, Lertudomphonwanit, C, Fischer, R, Larson-Nath, C, Mozer-Glassberg, Y, Arikan, C, Lin, H, Bernabeu, J, Alam, S, Kelly, D, Carvalho, E, Ferreira, C, Indolfi, G, Quiros-Tejeira, R, Bulut, P, Calvo, P, Anal, Z, Valentino, P, Desai, D, Eshun, J, Rogalidou, M, Dezsofi, A, Wiecek, S, Nebbia, G, Pinto, R, Wolters, V, Tamara, M, Zizzo, A, Garcia, J, Schwarz, K, Beretta, M, Sandahl, T, Jimenez-Rivera, C, Kerkar, N, Brecelj, J, Mujawar, Q, Rock, N, Busoms, C, Karnsakul, W, Lurz, E, Santos-Silva, E, Blondet, N, Bujanda, L, Shah, U, Thompson, R, Hansen, B, Kamath, B, Vandriel S. M., Li L. -T., She H., Wang J. -S., Gilbert M. A., Jankowska I., Czubkowski P., Gliwicz-Miedzinska D., Gonzales E. M., Jacquemin E., Bouligand J., Spinner N. B., Loomes K. M., Piccoli D. A., D'Antiga L., Nicastro E., Sokal A., Demaret T., Ebel N. H., Feinstein J. A., Fawaz R., Nastasio S., Lacaille F., Debray D., Arnell H., Fischler B., Siew S., Stormon M., Karpen S. J., Romero R., Kim K. M., Baek W. Y., Hardikar W., Shankar S., Roberts A. J., Evans H. M., Jensen M. K., Kavan M., Sundaram S. S., Chaidez A., Karthikeyan P., Sanchez M. C., Cavalieri M. L., Verkade H. J., Lee W. S., Squires J. E., Hajinicolaou C., Lertudomphonwanit C., Fischer R. T., Larson-Nath C., Mozer-Glassberg Y., Arikan C., Lin H. C., Bernabeu J. Q., Alam S., Kelly D. A., Carvalho E., Ferreira C. T., Indolfi G., Quiros-Tejeira R. E., Bulut P., Calvo P. L., Anal Z., Valentino P. L., Desai D. M., Eshun J., Rogalidou M., Dezsofi A., Wiecek S., Nebbia G., Pinto R. B., Wolters V. M., Tamara M. L., Zizzo A. N., Garcia J., Schwarz K., Beretta M., Sandahl T. D., Jimenez-Rivera C., Kerkar N., Brecelj J., Mujawar Q., Rock N., Busoms C. M., Karnsakul W., Lurz E., Santos-Silva E., Blondet N., Bujanda L., Shah U., Thompson R. J., Hansen B. E., and Kamath B. M.
- Abstract
Background and Aims: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real-world data are lacking. This study aimed to elucidate the natural history of liver disease in a contemporary, international cohort of children with ALGS. Approach and Results: This was a multicenter retrospective study of children with a clinically and/or genetically confirmed ALGS diagnosis, born between January 1997 and August 2019. Native liver survival (NLS) and event-free survival rates were assessed. Cox models were constructed to identify early biochemical predictors of clinically evident portal hypertension (CEPH) and NLS. In total, 1433 children (57% male) from 67 centers in 29 countries were included. The 10 and 18-year NLS rates were 54.4% and 40.3%. By 10 and 18 years, 51.5% and 66.0% of children with ALGS experienced ≥1 adverse liver-related event (CEPH, transplant, or death). Children (>6 and ≤12 months) with median total bilirubin (TB) levels between ≥5.0 and <10.0 mg/dl had a 4.1-fold (95% confidence interval [CI], 1.6-10.8), and those ≥10.0 mg/dl had an 8.0-fold (95% CI, 3.4-18.4) increased risk of developing CEPH compared with those <5.0 mg/dl. Median TB levels between ≥5.0 and <10.0 mg/dl and >10.0 mg/dl were associated with a 4.8 (95% CI, 2.4-9.7) and 15.6 (95% CI, 8.7-28.2) increased risk of transplantation relative to <5.0 mg/dl. Median TB <5.0 mg/dl were associated with higher NLS rates relative to ≥5.0 mg/dl, with 79% reaching adulthood with native liver (p < 0.001). Conclusions: In this large international cohort of ALGS, only 40.3% of children reach adulthood with their native liver. A TB <5.0 mg/dl between 6 and 12 months of age is associated with better hepatic outcomes. These thresholds provide clinicians with an objective tool to assist with clinical decision-making and in the evaluation of therapies.
- Published
- 2023
5. Long-term Outcome of Asymptomatic Patients with Graft Fibrosis in Protocol Biopsies after Pediatric Liver Transplantation
- Author
-
Hartleif, S, Hodson, J, Lloyd, C, Cousin, V, Czubkowski, P, D'Antiga, L, Debray, D, Demetris, A, Di Giorgio, A, Evans, H, Fischler, B, Gonzales, E, Gouw, A, Hubscher, S, Jacquemin, E, Lacaille, F, Malenicka, S, Mclin, V, Markiewicz-Kijewska, M, Mazariegos, G, Rajanayagam, J, Scheenstra, R, Singer, S, Smets, F, Sokal, E, Squires, J, Sturm, E, Verkade, H, Kelly, D, Hartleif S., Hodson J., Lloyd C., Cousin V. L., Czubkowski P., D'Antiga L., Debray D., Demetris A., Di Giorgio A., Evans H. M., Fischler B., Gonzales E., Gouw A. S. H., Hubscher S. G., Jacquemin E., Lacaille F., Malenicka S., McLin V. A., Markiewicz-Kijewska M., Mazariegos G. V., Rajanayagam J. K., Scheenstra R., Singer S., Smets F., Sokal E., Squires J. E., Sturm E., Verkade H., Kelly D. A., Hartleif, S, Hodson, J, Lloyd, C, Cousin, V, Czubkowski, P, D'Antiga, L, Debray, D, Demetris, A, Di Giorgio, A, Evans, H, Fischler, B, Gonzales, E, Gouw, A, Hubscher, S, Jacquemin, E, Lacaille, F, Malenicka, S, Mclin, V, Markiewicz-Kijewska, M, Mazariegos, G, Rajanayagam, J, Scheenstra, R, Singer, S, Smets, F, Sokal, E, Squires, J, Sturm, E, Verkade, H, Kelly, D, Hartleif S., Hodson J., Lloyd C., Cousin V. L., Czubkowski P., D'Antiga L., Debray D., Demetris A., Di Giorgio A., Evans H. M., Fischler B., Gonzales E., Gouw A. S. H., Hubscher S. G., Jacquemin E., Lacaille F., Malenicka S., McLin V. A., Markiewicz-Kijewska M., Mazariegos G. V., Rajanayagam J. K., Scheenstra R., Singer S., Smets F., Sokal E., Squires J. E., Sturm E., Verkade H., and Kelly D. A.
- Abstract
Background. The histological prevalence of allograft fibrosis in asymptomatic children after liver transplantation (LT) is well documented. However, long-term graft and patient survival remain unclear. This retrospective multicenter study aims to determine the prevalence of allograft fibrosis and analyze the long-term outcome for patients transplanted in childhood. Methods. We reviewed clinical data of children who had undergone 10-y protocol liver biopsies. We excluded patients with autoimmune hepatitis, primary sclerosing cholangitis, hepatitis B or C, and retransplantation. In total, 494 patients transplanted in childhood across 12 international transplant centers were included. We evaluated the development of fibrosis by comparing the results with biopsies obtained 5 and 15 y post-LT. Histological findings were correlated with graft and patient survival up to 20 y post-LT. Results. In the 10-y biopsies, periportal or pericentral fibrosis was observed in 253 patients (51%), 87 (18%) had bridging fibrosis, 30 (6%) had cirrhosis, and 124 (25%) had no fibrosis. The prevalence and stage of graft fibrosis significantly progressed from 5 to 10 y. At 10 y, the severity of fibrosis correlated significantly with inflammation. Patients with graft cirrhosis in the 10-y biopsy were more likely to die or require retransplantation subsequently (P = 0.027). Conclusions. At 10 y post-LT, most patients transplanted in childhood developed fibrosis, based on the protocol liver biopsies. Although mild-to-moderate graft fibrosis did not largely affect patient or graft survival up to 20 y post-LT, this progressive fibrosis finding has substantial implications for developing cirrhosis and portal hypertension in adult care.
- Published
- 2023
6. Disrupted BMP-9 signaling impairs pulmonary vascular integrity in hepatopulmonary syndrome
- Author
-
Robert, F., primary, Certain, M.C., additional, Baron, A., additional, Thuillet, R., additional, Duhaut, L., additional, Ottaviani, M., additional, Chelgham, M.K., additional, Normand, C., additional, Berrebeh, N., additional, Ricard, N., additional, Furlan, V., additional, Desroches-Castan, A., additional, Gonzales, E., additional, Jacquemin, E., additional, Sitbon, O., additional, Humbert, M., additional, Bailly, S., additional, Coilly, A., additional, Guignabert, C., additional, Tu, L., additional, and Savale, L., additional
- Published
- 2024
- Full Text
- View/download PDF
7. A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing
- Author
-
Denomme-Pichon A. -S., Bruel A. -L., Duffourd Y., Safraou H., Thauvin-Robinet C., Tran Mau-Them F., Philippe C., Vitobello A., Jean-Marcais N., Moutton S., Thevenon J., Faivre L., Matalonga L., de Boer E., Gilissen C., Hoischen A., Kleefstra T., Pfundt R., de Vries B. B. A., Willemsen M. H., Vissers L. E. L. M., Jackson A., Banka S., Clayton-Smith J., Benetti E., Fallerini C., Renieri A., Ciolfi A., Dallapiccola B., Pizzi S., Radio F. C., Tartaglia M., Ellwanger K., Graessner H., Haack T. B., Zurek B., Havlovicova M., Macek M., Ryba L., Schwarz M., Votypka P., Lopez-Martin E., Posada M., Mencarelli M. A., Rooryck C., Trimouille A., Verloes A., Abbott K. M., Kerstjens M., Martin E. L., Maystadt I., Morleo M., Nigro V., Pinelli M., Riess O., Agathe J. -M. D. S., Santen G. W. E., Thauvin C., Torella A., Vissers L., Zguro K., Boer E. D., Cohen E., Danis D., Gao F., Horvath R., Johari M., Johanson L., Li S., Morsy H., Nelson I., Paramonov I., te Paske I. B. A. W., Robinson P., Savarese M., Steyaert W., Topf A., van der Velde J. K., Vandrovcova J., Ossowski S., Demidov G., Sturm M., Schulze-Hentrich J. M., Schule R., Xu J., Kessler C., Wayand M., Synofzik M., Wilke C., Traschutz A., Schols L., Hengel H., Lerche H., Kegele J., Heutink P., Brunner H., Scheffer H., Hoogerbrugge N., 't Hoen P. A. C., Sablauskas K., de Voer R. M., Kamsteeg E. -J., van de Warrenburg B., van Os N., Paske I. T., Janssen E., Steehouwer M., Yaldiz B., Brookes A. J., Veal C., Gibson S., Maddi V., Mehtarizadeh M., Riaz U., Warren G., Dizjikan F. Y., Shorter T., Straub V., Bettolo C. M., Manera J. D., Hambleton S., Engelhardt K., Alexander E., Peyron C., Pelissier A., Beltran S., Gut I. G., Laurie S., Piscia D., Papakonstantinou A., Bullich G., Corvo A., Fernandez-Callejo M., Hernandez C., Pico D., Lochmuller H., Gumus G., Bros-Facer V., Rath A., Hanauer M., Lagorce D., Hongnat O., Chahdil M., Lebreton E., Stevanin G., Durr A., Davoine C. -S., Guillot-Noel L., Heinzmann A., Coarelli G., Bonne G., Evangelista T., Allamand V., Ben Yaou R., Metay C., Eymard B., Atalaia A., Stojkovic T., Turnovec M., Thomasova D., Kremlikova R. P., Frankova V., Liskova P., Dolezalova P., Parkinson H., Keane T., Freeberg M., Thomas C., Spalding D., Robert G., Costa A., Patch C., Hanna M., Houlden H., Reilly M., Efthymiou S., Cali E., Magrinelli F., Sisodiya S. M., Rohrer J., Muntoni F., Zaharieva I., Sarkozy A., Timmerman V., Baets J., de Vries G., De Winter J., Beijer D., de Jonghe P., Van de Vondel L., De Ridder W., Weckhuysen S., Mutarelli M., Varavallo A., Banfi S., Musacchia F., Piluso G., Ferlini A., Selvatici R., Gualandi F., Bigoni S., Rossi R., Neri M., Aretz S., Spier I., Sommer A. K., Peters S., Oliveira C., Pelaez J. G., Matos A. R., Jose C. S., Ferreira M., Gullo I., Fernandes S., Garrido L., Ferreira P., Carneiro F., Swertz M. A., Johansson L., van der Vries G., Neerincx P. B., Ruvolo D., Kerstjens Frederikse W. S., Zonneveld-Huijssoon E., Roelofs-Prins D., van Gijn M., Kohler S., Metcalfe A., Drunat S., Heron D., Mignot C., Keren B., Lacombe D., Capella G., Valle L., Holinski-Feder E., Laner A., Steinke-Lange V., Cilio M. -R., Carpancea E., Depondt C., Lederer D., Sznajer Y., Duerinckx S., Mary S., Macaya A., Cazurro-Gutierrez A., Perez-Duenas B., Munell F., Jarava C. F., Maso L. B., Marce-Grau A., Colobran R., Hackman P., Udd B., Hemelsoet D., Dermaut B., Schuermans N., Poppe B., Verdin H., Osorio A. N., Depienne C., Roos A., Cordts I., Deschauer M., Striano P., Zara F., Riva A., Iacomino M., Uva P., Scala M., Scudieri P., Basak A. N., Claeys K., Boztug K., Haimel M., W. E G., Ruivenkamp C. A. L., Natera de Benito D., Thompson R., Polavarapu K., Grimbacher B., Zaganas I., Kokosali E., Lambros M., Evangeliou A., Spilioti M., Kapaki E., Bourbouli M., Balicza P., Molnar M. J., De la Paz M. P., Sanchez E. B., Delgado B. M., Alonso Garcia de la Rosa F. J., Schrock E., Rump A., Mei D., Vetro A., Balestrini S., Guerrini R., Chinnery P. F., Ratnaike T., Schon K., Maver A., Peterlin B., Munchau A., Lohmann K., Herzog R., Pauly M., May P., Beeson D., Cossins J., Furini S., Afenjar A., Goldenberg A., Masurel A., Phan A., Dieux-Coeslier A., Fargeot A., Guerrot A. -M., Toutain A., Molin A., Sorlin A., Putoux A., Jouret B., Laudier B., Demeer B., Doray B., Bonniaud B., Isidor B., Gilbert-Dussardier B., Leheup B., Reversade B., Paul C., Vincent-Delorme C., Neiva C., Poirsier C., Quelin C., Chiaverini C., Coubes C., Francannet C., Colson C., Desplantes C., Wells C., Goizet C., Sanlaville D., Amram D., Lehalle D., Genevieve D., Gaillard D., Zivi E., Sarrazin E., Steichen E., Schaefer E., Lacaze E., Jacquemin E., Bongers E., Kilic E., Colin E., Giuliano F., Prieur F., Laffargue F., Morice-Picard F., Petit F., Cartault F., Feillet F., Baujat G., Morin G., Diene G., Journel H., Perthus I., Lespinasse J., Alessandri J. -L., Amiel J., Martinovic J., Delanne J., Albuisson J., Lambert L., Perrin L., Ousager L. B., Van Maldergem L., Pinson L., Ruaud L., Samimi M., Bournez M., Bonnet-Dupeyron M. N., Vincent M., Jacquemont M. -L., Cordier-Alex M. -P., Gerard-Blanluet M., Willems M., Spodenkiewicz M., Doco-Fenzy M., Rossi M., Renaud M., Fradin M., Mathieu M., Holder-Espinasse M. H., Houcinat N., Hanna N., Leperrier N., Chassaing N., Philip N., Boute O., Van Kien P. K., Parent P., Bitoun P., Sarda P., Vabres P., Jouk P. -S., Touraine R., El Chehadeh S., Whalen S., Marlin S., Passemard S., Grotto S., Bellanger S. A., Blesson S., Nambot S., Naudion S., Lyonnet S., Odent S., Attie-Bitach T., Busa T., Drouin-Garraud V., Layet V., Bizaoui V., Cusin V., Capri Y., Alembik Y., Unión Europea. Comisión Europea. H2020, Unión Europea. Comisión Europea. 7 Programa Marco, Instituto de Salud Carlos III, Instituto Nacional de Bioinformatica (España), Ministry of Health (República Checa), Ministry of Education, Youth and Sports (República Checa), Denomme-Pichon, A. -S., Bruel, A. -L., Duffourd, Y., Safraou, H., Thauvin-Robinet, C., Tran Mau-Them, F., Philippe, C., Vitobello, A., Jean-Marcais, N., Moutton, S., Thevenon, J., Faivre, L., Matalonga, L., de Boer, E., Gilissen, C., Hoischen, A., Kleefstra, T., Pfundt, R., de Vries, B. B. A., Willemsen, M. H., Vissers, L. E. L. M., Jackson, A., Banka, S., Clayton-Smith, J., Benetti, E., Fallerini, C., Renieri, A., Ciolfi, A., Dallapiccola, B., Pizzi, S., Radio, F. C., Tartaglia, M., Ellwanger, K., Graessner, H., Haack, T. B., Zurek, B., Havlovicova, M., Macek, M., Ryba, L., Schwarz, M., Votypka, P., Lopez-Martin, E., Posada, M., Mencarelli, M. A., Rooryck, C., Trimouille, A., Verloes, A., Abbott, K. M., Kerstjens, M., Martin, E. L., Maystadt, I., Morleo, M., Nigro, V., Pinelli, M., Riess, O., Agathe, J. -M. D. S., Santen, G. W. E., Thauvin, C., Torella, A., Vissers, L., Zguro, K., Boer, E. D., Cohen, E., Danis, D., Gao, F., Horvath, R., Johari, M., Johanson, L., Li, S., Morsy, H., Nelson, I., Paramonov, I., te Paske, I. B. A. W., Robinson, P., Savarese, M., Steyaert, W., Topf, A., van der Velde, J. K., Vandrovcova, J., Ossowski, S., Demidov, G., Sturm, M., Schulze-Hentrich, J. M., Schule, R., Xu, J., Kessler, C., Wayand, M., Synofzik, M., Wilke, C., Traschutz, A., Schols, L., Hengel, H., Lerche, H., Kegele, J., Heutink, P., Brunner, H., Scheffer, H., Hoogerbrugge, N., 't Hoen, P. A. C., Sablauskas, K., de Voer, R. M., Kamsteeg, E. -J., van de Warrenburg, B., van Os, N., Paske, I. T., Janssen, E., Steehouwer, M., Yaldiz, B., Brookes, A. J., Veal, C., Gibson, S., Maddi, V., Mehtarizadeh, M., Riaz, U., Warren, G., Dizjikan, F. Y., Shorter, T., Straub, V., Bettolo, C. M., Manera, J. D., Hambleton, S., Engelhardt, K., Alexander, E., Peyron, C., Pelissier, A., Beltran, S., Gut, I. G., Laurie, S., Piscia, D., Papakonstantinou, A., Bullich, G., Corvo, A., Fernandez-Callejo, M., Hernandez, C., Pico, D., Lochmuller, H., Gumus, G., Bros-Facer, V., Rath, A., Hanauer, M., Lagorce, D., Hongnat, O., Chahdil, M., Lebreton, E., Stevanin, G., Durr, A., Davoine, C. -S., Guillot-Noel, L., Heinzmann, A., Coarelli, G., Bonne, G., Evangelista, T., Allamand, V., Ben Yaou, R., Metay, C., Eymard, B., Atalaia, A., Stojkovic, T., Turnovec, M., Thomasova, D., Kremlikova, R. P., Frankova, V., Liskova, P., Dolezalova, P., Parkinson, H., Keane, T., Freeberg, M., Thomas, C., Spalding, D., Robert, G., Costa, A., Patch, C., Hanna, M., Houlden, H., Reilly, M., Efthymiou, S., Cali, E., Magrinelli, F., Sisodiya, S. M., Rohrer, J., Muntoni, F., Zaharieva, I., Sarkozy, A., Timmerman, V., Baets, J., de Vries, G., De Winter, J., Beijer, D., de Jonghe, P., Van de Vondel, L., De Ridder, W., Weckhuysen, S., Mutarelli, M., Varavallo, A., Banfi, S., Musacchia, F., Piluso, G., Ferlini, A., Selvatici, R., Gualandi, F., Bigoni, S., Rossi, R., Neri, M., Aretz, S., Spier, I., Sommer, A. K., Peters, S., Oliveira, C., Pelaez, J. G., Matos, A. R., Jose, C. S., Ferreira, M., Gullo, I., Fernandes, S., Garrido, L., Ferreira, P., Carneiro, F., Swertz, M. A., Johansson, L., van der Vries, G., Neerincx, P. B., Ruvolo, D., Kerstjens Frederikse, W. S., Zonneveld-Huijssoon, E., Roelofs-Prins, D., van Gijn, M., Kohler, S., Metcalfe, A., Drunat, S., Heron, D., Mignot, C., Keren, B., Lacombe, D., Capella, G., Valle, L., Holinski-Feder, E., Laner, A., Steinke-Lange, V., Cilio, M. -R., Carpancea, E., Depondt, C., Lederer, D., Sznajer, Y., Duerinckx, S., Mary, S., Macaya, A., Cazurro-Gutierrez, A., Perez-Duenas, B., Munell, F., Jarava, C. F., Maso, L. B., Marce-Grau, A., Colobran, R., Hackman, P., Udd, B., Hemelsoet, D., Dermaut, B., Schuermans, N., Poppe, B., Verdin, H., Osorio, A. N., Depienne, C., Roos, A., Cordts, I., Deschauer, M., Striano, P., Zara, F., Riva, A., Iacomino, M., Uva, P., Scala, M., Scudieri, P., Basak, A. N., Claeys, K., Boztug, K., Haimel, M., W. E, G., Ruivenkamp, C. A. L., Natera de Benito, D., Thompson, R., Polavarapu, K., Grimbacher, B., Zaganas, I., Kokosali, E., Lambros, M., Evangeliou, A., Spilioti, M., Kapaki, E., Bourbouli, M., Balicza, P., Molnar, M. J., De la Paz, M. P., Sanchez, E. B., Delgado, B. M., Alonso Garcia de la Rosa, F. J., Schrock, E., Rump, A., Mei, D., Vetro, A., Balestrini, S., Guerrini, R., Chinnery, P. F., Ratnaike, T., Schon, K., Maver, A., Peterlin, B., Munchau, A., Lohmann, K., Herzog, R., Pauly, M., May, P., Beeson, D., Cossins, J., Furini, S., Afenjar, A., Goldenberg, A., Masurel, A., Phan, A., Dieux-Coeslier, A., Fargeot, A., Guerrot, A. -M., Toutain, A., Molin, A., Sorlin, A., Putoux, A., Jouret, B., Laudier, B., Demeer, B., Doray, B., Bonniaud, B., Isidor, B., Gilbert-Dussardier, B., Leheup, B., Reversade, B., Paul, C., Vincent-Delorme, C., Neiva, C., Poirsier, C., Quelin, C., Chiaverini, C., Coubes, C., Francannet, C., Colson, C., Desplantes, C., Wells, C., Goizet, C., Sanlaville, D., Amram, D., Lehalle, D., Genevieve, D., Gaillard, D., Zivi, E., Sarrazin, E., Steichen, E., Schaefer, E., Lacaze, E., Jacquemin, E., Bongers, E., Kilic, E., Colin, E., Giuliano, F., Prieur, F., Laffargue, F., Morice-Picard, F., Petit, F., Cartault, F., Feillet, F., Baujat, G., Morin, G., Diene, G., Journel, H., Perthus, I., Lespinasse, J., Alessandri, J. -L., Amiel, J., Martinovic, J., Delanne, J., Albuisson, J., Lambert, L., Perrin, L., Ousager, L. B., Van Maldergem, L., Pinson, L., Ruaud, L., Samimi, M., Bournez, M., Bonnet-Dupeyron, M. N., Vincent, M., Jacquemont, M. -L., Cordier-Alex, M. -P., Gerard-Blanluet, M., Willems, M., Spodenkiewicz, M., Doco-Fenzy, M., Rossi, M., Renaud, M., Fradin, M., Mathieu, M., Holder-Espinasse, M. H., Houcinat, N., Hanna, N., Leperrier, N., Chassaing, N., Philip, N., Boute, O., Van Kien, P. K., Parent, P., Bitoun, P., Sarda, P., Vabres, P., Jouk, P. -S., Touraine, R., El Chehadeh, S., Whalen, S., Marlin, S., Passemard, S., Grotto, S., Bellanger, S. A., Blesson, S., Nambot, S., Naudion, S., Lyonnet, S., Odent, S., Attie-Bitach, T., Busa, T., Drouin-Garraud, V., Layet, V., Bizaoui, V., Cusin, V., Capri, Y., Alembik, Y., and Luxembourg Centre for Systems Biomedicine (LCSB): Bioinformatics Core (R. Schneider Group) [research center]
- Subjects
Exome reanalysis ,Neurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7] ,Multidisciplinaire, généralités & autres [D99] [Sciences de la santé humaine] ,Developmental disorder ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Biology and Life Sciences ,Metabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6] ,ClinVar ,Rare diseases ,All institutes and research themes of the Radboud University Medical Center ,Medicine and Health Sciences ,Genetics & genetic processes [F10] [Life sciences] ,Génétique & processus génétiques [F10] [Sciences du vivant] ,Multidisciplinary, general & others [D99] [Human health sciences] ,Exome reanalysi ,Genetics (clinical) - Abstract
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock. The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which received funding from the EU projects RD-Connect, Solve-RD, and European Joint Programme on Rare Diseases (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática), and ELIXIR Implementation Studies. The collaborations in this study were facilitated by the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies, one of the 24 European Reference Networks approved by the European Reference Network Board of Member States, cofunded by the European Commission. This project was supported by the Czech Ministry of Health (number 00064203) and by the Czech Ministry of Education, Youth and Sports (number - LM2018132) to M.M. Sí
- Published
- 2023
- Full Text
- View/download PDF
8. Prognosis of Children Undergoing Liver Transplantation: A 30-Year European Study
- Author
-
Baumann, U, Karam, V, Adam, R, Fondevila, C, Dhawan, A, Sokal, E, Jacquemin, E, Kelly, D, Grabhorn, E, Pawlowska, J, D'Antiga, L, Vega, P, Debray, D, Polak, W, de Ville de Goyet, J, Verkade, H, Baumann U., Karam V., Adam R., Fondevila C., Dhawan A., Sokal E., Jacquemin E., Kelly D. A., Grabhorn E., Pawlowska J., D'Antiga L., Vega P. J., Debray D., Polak W. G., de Ville de Goyet J., Verkade H. J., Baumann, U, Karam, V, Adam, R, Fondevila, C, Dhawan, A, Sokal, E, Jacquemin, E, Kelly, D, Grabhorn, E, Pawlowska, J, D'Antiga, L, Vega, P, Debray, D, Polak, W, de Ville de Goyet, J, Verkade, H, Baumann U., Karam V., Adam R., Fondevila C., Dhawan A., Sokal E., Jacquemin E., Kelly D. A., Grabhorn E., Pawlowska J., D'Antiga L., Vega P. J., Debray D., Polak W. G., de Ville de Goyet J., and Verkade H. J.
- Abstract
OBJECTIVES: The European Liver Transplant Registry has been collecting data on virtually all pediatric liver transplant (PLT) procedures in Europe since 1968. We analyzed patient outcome over time and identified parameters associated with long-term patient outcome. METHODS: Participating centers and European organ-sharing organizations provided retrospective data to the European Liver Transplant Registry. To identify trends, data were grouped into consecutive time spans: era A: before 2000, era B: 2000 to 2009, and the current era, era C: since 2010. RESULTS: From June 1968 until December 2017, 16 641 PLT were performed on 14 515 children by 133 centers. The children <7 years of age represented 58% in era A, and 66% in the current era (P <.01). The main indications for PLT were congenital biliary diseases (44%) and metabolic diseases (18%). Patient survival at 5 years is currently 86% overall and 97% in children who survive the first year after PLT. The survival rate has improved from 74% in era A to 83% in era B and 85% in era C (P <.0001). Low-volume centers (<5 PLT/year) represented 75% of centers but performed only 19% of PLT and were associated with a decreased survival rate. In the current era, however, survival rates has become irrespective of volume. Infection is the leading cause of death (4.1%), followed by primary nonfunction of the graft (1.4%). CONCLUSIONS: PLT has become a highly successful medical treatment that should be considered for all children with end-stage liver disease. The main challenge for further improving the prognosis remains the early postoperative period.
- Published
- 2022
9. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency
- Author
-
Felzen, A. van Wessel, D.B.E. Gonzales, E. Thompson, R.J. Jankowska, I. Shneider, B.L. Sokal, E. Grammatikopoulos, T. Kadaristiana, A. Jacquemin, E. Spraul, A. Lipiński, P. Czubkowski, P. Rock, N. Shagrani, M. Broering, D. Nicastro, E. Kelly, D. Nebbia, G. Arnell, H. Fischler, B. Hulscher, J.B.F. Serranti, D. Arikan, C. Polat, E. Debray, D. Lacaille, F. Goncalves, C. Hierro, L. Muñoz Bartolo, G. Mozer-Glassberg, Y. Azaz, A. Brecelj, J. Dezsőfi, A. Calvo, P.L. Grabhorn, E. Hartleif, S. van der Woerd, W.J. Kamath, B.M. Wang, J.-S. Li, L. Durmaz, Ö. Kerkar, N. Jørgensen, M.H. Fischer, R. Jimenez-Rivera, C. Alam, S. Cananzi, M. Laverdure, N. Ferreira, C.T. Guerrero, F.O. Wang, H. Sency, V. Kim, K.M. Chen, H.-L. de Carvalho, E. Fabre, A. Bernabeu, J.Q. Zellos, A. Alonso, E.M. Sokol, R.J. Suchy, F.J. Loomes, K.M. McKiernan, P.J. Rosenthal, P. Turmelle, Y. Horslen, S. Schwarz, K. Bezerra, J.A. Wang, K. Hansen, B.E. Verkade, H.J. the NAtural course Prognosis of PFIC Effect of biliary Diversion (NAPPED) Consortium and Felzen, A. van Wessel, D.B.E. Gonzales, E. Thompson, R.J. Jankowska, I. Shneider, B.L. Sokal, E. Grammatikopoulos, T. Kadaristiana, A. Jacquemin, E. Spraul, A. Lipiński, P. Czubkowski, P. Rock, N. Shagrani, M. Broering, D. Nicastro, E. Kelly, D. Nebbia, G. Arnell, H. Fischler, B. Hulscher, J.B.F. Serranti, D. Arikan, C. Polat, E. Debray, D. Lacaille, F. Goncalves, C. Hierro, L. Muñoz Bartolo, G. Mozer-Glassberg, Y. Azaz, A. Brecelj, J. Dezsőfi, A. Calvo, P.L. Grabhorn, E. Hartleif, S. van der Woerd, W.J. Kamath, B.M. Wang, J.-S. Li, L. Durmaz, Ö. Kerkar, N. Jørgensen, M.H. Fischer, R. Jimenez-Rivera, C. Alam, S. Cananzi, M. Laverdure, N. Ferreira, C.T. Guerrero, F.O. Wang, H. Sency, V. Kim, K.M. Chen, H.-L. de Carvalho, E. Fabre, A. Bernabeu, J.Q. Zellos, A. Alonso, E.M. Sokol, R.J. Suchy, F.J. Loomes, K.M. McKiernan, P.J. Rosenthal, P. Turmelle, Y. Horslen, S. Schwarz, K. Bezerra, J.A. Wang, K. Hansen, B.E. Verkade, H.J. the NAtural course Prognosis of PFIC Effect of biliary Diversion (NAPPED) Consortium
- Abstract
Background & Aims: Bile salt export pump (BSEP) deficiency frequently necessitates liver transplantation in childhood. In contrast to two predicted protein truncating mutations (PPTMs), homozygous p.D482G or p.E297G mutations are associated with relatively mild phenotypes, responsive to surgical interruption of the enterohepatic circulation (siEHC). The phenotype of patients with a compound heterozygous genotype of one p.D482G or p.E297G mutation and one PPTM has remained unclear. We aimed to assess their genotype-phenotype relationship. Methods: From the NAPPED database, we selected patients with homozygous p.D482G or p.E297G mutations (BSEP1/1; n = 31), with one p.D482G or p.E297G, and one PPTM (BSEP1/3; n = 30), and with two PPTMs (BSEP3/3; n = 77). We compared clinical presentation, native liver survival (NLS), and the effect of siEHC on NLS. Results: The groups had a similar median age at presentation (0.7-1.3 years). Overall NLS at age 10 years was 21% in BSEP1/3 vs. 75% in BSEP1/1 and 23% in BSEP3/3 (p <0.001). Without siEHC, NLS in the BSEP1/3 group was similar to that in BSEP3/3, but considerably lower than in BSEP1/1 (at age 10 years: 38%, 30%, and 71%, respectively; p = 0.003). After siEHC, BSEP1/3 and BSEP3/3 were associated with similarly low NLS, while NLS was much higher in BSEP1/1 (10 years after siEHC, 27%, 14%, and 92%, respectively; p <0.001). Conclusions: Individuals with BSEP deficiency with one p.E297G or p.D482G mutation and one PPTM have a similarly severe disease course and low responsiveness to siEHC as those with two PPTMs. This identifies a considerable subgroup of patients who are unlikely to benefit from interruption of the enterohepatic circulation by either surgical or ileal bile acid transporter inhibitor treatment. Impact and implications: This manuscript defines the clinical features and prognosis of individuals with BSEP deficiency involving the combination of one relatively mild and one very severe BSEP deficiency mutat
- Published
- 2023
10. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study
- Author
-
Vandriel, SM, Li, L-T, She, H, Wang, J-S, Gilbert, MA, Jankowska, I, Czubkowski, P, Gliwicz-Miedzinska, D, Gonzales, EM, Jacquemin, E, Bouligand, J, Spinner, NB, Loomes, KM, Piccoli, DA, D'Antiga, L, Nicastro, E, Sokal, E, Demaret, T, Ebel, NH, Feinstein, JA, Fawaz, R, Nastasio, S, Lacaille, F, Debray, D, Arnell, H, Fischler, B, Siew, S, Stormon, M, Karpen, SJ, Romero, R, Kim, KM, Baek, WY, Hardikar, W, Shankar, S, Roberts, AJ, Evans, HM, Jensen, MK, Kavan, M, Sundaram, SS, Chaidez, A, Karthikeyan, P, Sanchez, MC, Cavalieri, ML, Verkade, HJ, Lee, WS, Squires, JE, Hajinicolaou, C, Lertudomphonwanit, C, Fischer, RT, Larson-Nath, C, Mozer-Glassberg, Y, Arikan, C, Lin, HC, Bernabeu, JQ, Alam, S, Kelly, DA, Carvalho, E, Ferreira, CT, Indolfi, G, Quiros-Tejeira, RE, Bulut, P, Calvo, PL, Onal, Z, Valentino, PL, Desai, DM, Eshun, J, Rogalidou, M, Dezsofi, A, Wiecek, S, Nebbia, G, Pinto, RB, Wolters, VM, Tamara, ML, Zizzo, AN, Garcia, J, Schwarz, K, Beretta, M, Sandahl, TD, Jimenez-Rivera, C, Kerkar, N, Brecelj, J, Mujawar, Q, Rock, N, Busoms, CM, Karnsakul, W, Lurz, E, Santos-Silva, E, Blondet, N, Bujanda, L, Shah, U, Thompson, RJ, Hansen, BE, Kamath, BM, Vandriel, SM, Li, L-T, She, H, Wang, J-S, Gilbert, MA, Jankowska, I, Czubkowski, P, Gliwicz-Miedzinska, D, Gonzales, EM, Jacquemin, E, Bouligand, J, Spinner, NB, Loomes, KM, Piccoli, DA, D'Antiga, L, Nicastro, E, Sokal, E, Demaret, T, Ebel, NH, Feinstein, JA, Fawaz, R, Nastasio, S, Lacaille, F, Debray, D, Arnell, H, Fischler, B, Siew, S, Stormon, M, Karpen, SJ, Romero, R, Kim, KM, Baek, WY, Hardikar, W, Shankar, S, Roberts, AJ, Evans, HM, Jensen, MK, Kavan, M, Sundaram, SS, Chaidez, A, Karthikeyan, P, Sanchez, MC, Cavalieri, ML, Verkade, HJ, Lee, WS, Squires, JE, Hajinicolaou, C, Lertudomphonwanit, C, Fischer, RT, Larson-Nath, C, Mozer-Glassberg, Y, Arikan, C, Lin, HC, Bernabeu, JQ, Alam, S, Kelly, DA, Carvalho, E, Ferreira, CT, Indolfi, G, Quiros-Tejeira, RE, Bulut, P, Calvo, PL, Onal, Z, Valentino, PL, Desai, DM, Eshun, J, Rogalidou, M, Dezsofi, A, Wiecek, S, Nebbia, G, Pinto, RB, Wolters, VM, Tamara, ML, Zizzo, AN, Garcia, J, Schwarz, K, Beretta, M, Sandahl, TD, Jimenez-Rivera, C, Kerkar, N, Brecelj, J, Mujawar, Q, Rock, N, Busoms, CM, Karnsakul, W, Lurz, E, Santos-Silva, E, Blondet, N, Bujanda, L, Shah, U, Thompson, RJ, Hansen, BE, and Kamath, BM
- Abstract
BACKGROUND AND AIMS: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real-world data are lacking. This study aimed to elucidate the natural history of liver disease in a contemporary, international cohort of children with ALGS. APPROACH AND RESULTS: This was a multicenter retrospective study of children with a clinically and/or genetically confirmed ALGS diagnosis, born between January 1997 and August 2019. Native liver survival (NLS) and event-free survival rates were assessed. Cox models were constructed to identify early biochemical predictors of clinically evident portal hypertension (CEPH) and NLS. In total, 1433 children (57% male) from 67 centers in 29 countries were included. The 10 and 18-year NLS rates were 54.4% and 40.3%. By 10 and 18 years, 51.5% and 66.0% of children with ALGS experienced ≥1 adverse liver-related event (CEPH, transplant, or death). Children (>6 and ≤12 months) with median total bilirubin (TB) levels between ≥5.0 and <10.0 mg/dl had a 4.1-fold (95% confidence interval [CI], 1.6-10.8), and those ≥10.0 mg/dl had an 8.0-fold (95% CI, 3.4-18.4) increased risk of developing CEPH compared with those <5.0 mg/dl. Median TB levels between ≥5.0 and <10.0 mg/dl and >10.0 mg/dl were associated with a 4.8 (95% CI, 2.4-9.7) and 15.6 (95% CI, 8.7-28.2) increased risk of transplantation relative to <5.0 mg/dl. Median TB <5.0 mg/dl were associated with higher NLS rates relative to ≥5.0 mg/dl, with 79% reaching adulthood with native liver ( p < 0.001). CONCLUSIONS: In this large international cohort of ALGS, only 40.3% of children reach adulthood with their native liver. A TB <5.0 mg/dl between 6 and 12 months of age is associated with better hepatic outcomes. These thresholds provide clinicians with an objective tool to assist with clinical decision-making and in the evaluation of therapies.
- Published
- 2023
11. Individual distribution of muscle hypertrophy among hamstring muscle heads: Adding muscle volume where you need is not so simple.
- Author
-
Frouin, A., Le Sant, G., Barbier, L., Jacquemin, E., McNair, P. J., Ellis, R., Nordez, A., and Lacourpaille, L.
- Subjects
TENDON physiology ,EXERCISE physiology ,WEIGHT-bearing (Orthopedics) ,MUSCULAR hypertrophy ,SKELETAL muscle ,EXERCISE ,THREE-dimensional imaging ,HAMSTRING muscle ,STATISTICAL sampling ,ACHILLES tendon ,ULTRASONIC imaging ,DESCRIPTIVE statistics ,RESISTANCE training ,BLOOD flow restriction training - Abstract
Purpose: The aim of this study was to determine whether a 9‐week resistance training program based on high load (HL) versus low load combined with blood flow restriction (LL‐BFR) induced a similar (i) distribution of muscle hypertrophy among hamstring heads (semimembranosus, SM; semitendinosus, ST; and biceps femoris long head, BF) and (ii) magnitude of tendon hypertrophy of ST, using a parallel randomized controlled trial. Methods: A total of 45 participants were randomly allocated to one of three groups: HL, LL‐BFR, and control (CON). Both HL and LL‐BFR performed a 9‐week resistance training program composed of seated leg curl and stiff‐leg deadlift exercises. Freehand 3D ultrasound was used to assess the changes in muscle and tendon volume. Results: The increase in ST volume was greater in HL (26.5 ± 25.5%) compared to CON (p = 0.004). No difference was found between CON and LL‐BFR for the ST muscle volume (p = 0.627). The change in SM muscle volume was greater for LL‐BFR (21.6 ± 27.8%) compared to CON (p = 0.025). No difference was found between HL and CON for the SM muscle volume (p = 0.178).There was no change in BF muscle volume in LL‐BFR (14.0 ± 16.5%; p = 0.436) compared to CON group. No difference was found between HL and CON for the BF muscle volume (p = 1.0). Regarding ST tendon volume, we did not report an effect of training regimens (p = 0.411). Conclusion: These results provide evidence that the HL program induced a selective hypertrophy of the ST while LL‐BFR induced hypertrophy of SM. The magnitude of the selective hypertrophy observed within each group varied greatly between individuals. This finding suggests that it is very difficult to early determine the location of the hypertrophy among a muscle group. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Ictères de l’enfant
- Author
-
Gonzalès, E., primary, Habes, D., additional, Hermeziu, B., additional, and Jacquemin, E., additional
- Published
- 2018
- Full Text
- View/download PDF
13. Hépatites virales
- Author
-
Ackermann, O., primary, Thébaut, A., additional, Jacquemin, E., additional, and Gonzalès, E., additional
- Published
- 2018
- Full Text
- View/download PDF
14. 70 - Hépatites virales
- Author
-
Ackermann, O., Thébaut, A., Jacquemin, E., and Gonzalès, E.
- Published
- 2023
- Full Text
- View/download PDF
15. Long-term Follow-up of a Randomized Trial of Tacrolimus or Cyclosporine A Microemulsion in Children Post Liver Transplantation
- Author
-
Lloyd, C, Arshad, A, Jara, P, Burdelski, M, Gridelli, B, Manzanares, J, Colledan, M, Jacquemin, E, Reding, R, Baumann, U, Kelly, D, Lloyd C., Arshad A., Jara P., Burdelski M., Gridelli B., Manzanares J., Colledan M., Jacquemin E., Reding R., Baumann U., Kelly D., Lloyd, C, Arshad, A, Jara, P, Burdelski, M, Gridelli, B, Manzanares, J, Colledan, M, Jacquemin, E, Reding, R, Baumann, U, Kelly, D, Lloyd C., Arshad A., Jara P., Burdelski M., Gridelli B., Manzanares J., Colledan M., Jacquemin E., Reding R., Baumann U., and Kelly D.
- Abstract
Background. The aim of this study was to determine the long-term efficacy and safety of tacrolimus (Tac) and cyclosporine immunosuppression in pediatric liver transplantation (LTx). Methods. One hundred fifty-six patients who had taken part in a multicenter, randomized, open, parallel study of Tac and corticosteroids versus cyclosporine A microemulsion (CyA-ME), corticosteroids, and azathioprine. Patients were assessed at regular intervals up to 14 y after LTx. Analysis was conducted descriptively. Results. In a long-term follow-up, there was a similar incidence of acute rejection (Tac versus CyA-ME, 5 versus 8) and graft loss (5 versus 10). There were 11 deaths in the cohort, which were from infectious complications/malignancy in the Tac group (n = 2/5) and from chronic rejection/liver failure in the CyA-ME group (n = 3/6). A similar incidence of Epstein-Barr virus and posttransplant lymphoproliferative disease was observed (8 versus 8, 3 versus 3). However, there was a greater incidence of cosmetic adverse events in the CyA-ME cohort, with higher incidences of hypertrichosis (8 versus 27) and gum hyperplasia (20 versus 6). Growth improved equally in both groups. Overall, 81% of patients randomized to Tac remained on Tac therapy at study end, compared with 31% of patients randomized to CyA-ME. Common reasons for switching from CyA-ME included steroid-resistant/acute rejection (n = 12/8) and cosmetic changes (n = 8). Conclusions. This study is the first prospective, observational follow-up study of pediatric patients randomized to Tac and CyA-ME to evaluate long-term outcomes. Our analysis was limited by the degree of switchover between the cohorts; however, there were fewer deaths from chronic rejection/liver failure and reduced adverse events with Tac. Long-term use of Tac and Tac combination therapy appears to be safe and effective immunosuppression for pediatric LTx recipients.
- Published
- 2021
16. Allergies alimentaires et transplantations
- Author
-
Decline, J.-L., primary, Cohen, J., additional, Taoufik, Y., additional, and Jacquemin, E., additional
- Published
- 2017
- Full Text
- View/download PDF
17. The Long-Term Outcome of Hepatic Artery Thrombosis After Liver Transplantation in Children: Role of Urgent Revascularization
- Author
-
Ackermann, O., Branchereau, S., Franchi-Abella, S., Pariente, D., Chevret, L., Debray, D., Jacquemin, E., Gauthier, F., Hill, C., and Bernard, O.
- Published
- 2012
- Full Text
- View/download PDF
18. Pathotypes of Bovine Verotoxigenic Escherichia coli Isolates Producing Attaching/Effacing (AE) Lesions in the Ligated Intestinal Loop Assay in Rabbits
- Author
-
China, B., Pirson, V., Jacquemin, E., Pohl, P., Mainil, J. G., Paul, Prem S., editor, Francis, David H., editor, and Benfield, David A., editor
- Published
- 1997
- Full Text
- View/download PDF
19. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study
- Author
-
Vandriel, S.M. Li, L.-T. She, H. Wang, J.-S. Gilbert, M.A. Jankowska, I. Czubkowski, P. Gliwicz-Miedzińska, D. Gonzales, E.M. Jacquemin, E. Bouligand, J. Spinner, N.B. Loomes, K.M. Piccoli, D.A. D'Antiga, L. Nicastro, E. Sokal, É. Demaret, T. Ebel, N.H. Feinstein, J.A. Fawaz, R. Nastasio, S. Lacaille, F. Debray, D. Arnell, H. Fischler, B. Siew, S. Stormon, M. Karpen, S.J. Romero, R. Kim, K.M. Baek, W.Y. Hardikar, W. Shankar, S. Roberts, A.J. Evans, H.M. Jensen, M.K. Kavan, M. Sundaram, S.S. Chaidez, A. Karthikeyan, P. Sanchez, M.C. Cavalieri, M.L. Verkade, H.J. Lee, W.S. Squires, J.E. Hajinicolaou, C. Lertudomphonwanit, C. Fischer, R.T. Larson-Nath, C. Mozer-Glassberg, Y. Arikan, C. Lin, H.C. Bernabeu, J.Q. Alam, S. Kelly, D.A. Carvalho, E. Ferreira, C.T. Indolfi, G. Quiros-Tejeira, R.E. Bulut, P. Calvo, P.L. Önal, Z. Valentino, P.L. Desai, D.M. Eshun, J. Rogalidou, M. Dezsőfi, A. Wiecek, S. Nebbia, G. Pinto, R.B. Wolters, V.M. Tamara, M.L. Zizzo, A.N. Garcia, J. Schwarz, K. Beretta, M. Sandahl, T.D. Jimenez-Rivera, C. Kerkar, N. Brecelj, J. Mujawar, Q. Rock, N. Busoms, C.M. Karnsakul, W. Lurz, E. Santos-Silva, E. Blondet, N. Bujanda, L. Shah, U. Thompson, R.J. Hansen, B.E. Kamath, B.M. The Global ALagille Alliance (GALA) Study Group and Vandriel, S.M. Li, L.-T. She, H. Wang, J.-S. Gilbert, M.A. Jankowska, I. Czubkowski, P. Gliwicz-Miedzińska, D. Gonzales, E.M. Jacquemin, E. Bouligand, J. Spinner, N.B. Loomes, K.M. Piccoli, D.A. D'Antiga, L. Nicastro, E. Sokal, É. Demaret, T. Ebel, N.H. Feinstein, J.A. Fawaz, R. Nastasio, S. Lacaille, F. Debray, D. Arnell, H. Fischler, B. Siew, S. Stormon, M. Karpen, S.J. Romero, R. Kim, K.M. Baek, W.Y. Hardikar, W. Shankar, S. Roberts, A.J. Evans, H.M. Jensen, M.K. Kavan, M. Sundaram, S.S. Chaidez, A. Karthikeyan, P. Sanchez, M.C. Cavalieri, M.L. Verkade, H.J. Lee, W.S. Squires, J.E. Hajinicolaou, C. Lertudomphonwanit, C. Fischer, R.T. Larson-Nath, C. Mozer-Glassberg, Y. Arikan, C. Lin, H.C. Bernabeu, J.Q. Alam, S. Kelly, D.A. Carvalho, E. Ferreira, C.T. Indolfi, G. Quiros-Tejeira, R.E. Bulut, P. Calvo, P.L. Önal, Z. Valentino, P.L. Desai, D.M. Eshun, J. Rogalidou, M. Dezsőfi, A. Wiecek, S. Nebbia, G. Pinto, R.B. Wolters, V.M. Tamara, M.L. Zizzo, A.N. Garcia, J. Schwarz, K. Beretta, M. Sandahl, T.D. Jimenez-Rivera, C. Kerkar, N. Brecelj, J. Mujawar, Q. Rock, N. Busoms, C.M. Karnsakul, W. Lurz, E. Santos-Silva, E. Blondet, N. Bujanda, L. Shah, U. Thompson, R.J. Hansen, B.E. Kamath, B.M. The Global ALagille Alliance (GALA) Study Group
- Abstract
Background and Aims: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real-world data are lacking. This study aimed to elucidate the natural history of liver disease in a contemporary, international cohort of children with ALGS. Approach and Results: This was a multicenter retrospective study of children with a clinically and/or genetically confirmed ALGS diagnosis, born between January 1997 and August 2019. Native liver survival (NLS) and event-free survival rates were assessed. Cox models were constructed to identify early biochemical predictors of clinically evident portal hypertension (CEPH) and NLS. In total, 1433 children (57% male) from 67 centers in 29 countries were included. The 10 and 18-year NLS rates were 54.4% and 40.3%. By 10 and 18 years, 51.5% and 66.0% of children with ALGS experienced ≥1 adverse liver-related event (CEPH, transplant, or death). Children (>6 and ≤12 months) with median total bilirubin (TB) levels between ≥5.0 and <10.0 mg/dl had a 4.1-fold (95% confidence interval [CI], 1.6–10.8), and those ≥10.0 mg/dl had an 8.0-fold (95% CI, 3.4–18.4) increased risk of developing CEPH compared with those <5.0 mg/dl. Median TB levels between ≥5.0 and <10.0 mg/dl and >10.0 mg/dl were associated with a 4.8 (95% CI, 2.4–9.7) and 15.6 (95% CI, 8.7–28.2) increased risk of transplantation relative to <5.0 mg/dl. Median TB <5.0 mg/dl were associated with higher NLS rates relative to ≥5.0 mg/dl, with 79% reaching adulthood with native liver (p < 0.001). Conclusions: In this large international cohort of ALGS, only 40.3% of children reach adulthood with their native liver. A TB <5.0 mg/dl between 6 and 12 months of age is associated with better hepatic outcomes. These thresholds provide clinicians with an objective tool to assist with clinical decision-making and in the evaluation of therapies. © 2022 The Authors. Hepatology publ
- Published
- 2022
20. Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from The GALA Study
- Author
-
Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), Vandriel, S.M.; Li, L.T.; She, H.; Wang, J.S.; Gilbert, M.A.; Jankowska, I.; Czubkowski, P.; Gliwicz-Miedzi?ska, D.; Gonzales, E.M.; Jacquemin, E.; Bouligand, J.; Spinner, N.B.; Loomes, K.M.; Piccoli, D.A.; D'Antiga, L.; Nicastro, E.; Sokal, É.; Demaret, T.; Ebel, N.H.; Feinstein, J.A.; Fawaz, R.; Nastasio, S.; Lacaille, F.; Debray, D.; Arnell, H.; Fischler, B.; Siew, S.; Stormon, M.; Karpen, S.J.; Romero, R.; Kim, K.M.; Baek, W.Y.; Hardikar, W.; Shankar, S.; Roberts, A.J.; Evans, H.M.; Jensen, M.K.; Kavan, M.; Sundaram, S.S.; Chaidez, A.; Karthikeyan, P.; Sanchez, M.C.; Cavalieri, M.L.; Verkade, H.J.; Lee, W.S.; Squires, J.E.; Hajinicolaou, C.; Lertudomphonwanit, C.; Fischer, R.T.; Larson-Nath, C.; Mozer-Glassberg, Y.; Lin, H.C.; Quintero, Bernabeu J.; Alam, S.; Kelly, D.; Carvalho, E.; Ferreira, C.T.; Indolfi, G.; Quiros-Tejeira, R.E.; Bulut, P.; Calvo, P.L.; Önal, Z.; Valentino, P.L.; Desai, D.M.; Eshun, J.; Rogalidou, M.; Dezs?fi, A.; Wiecek, S.; Nebbia, G.; Borges Pinto, R.; Wolters, V.M.; Tamara, M.L.; Zizzo, A.N.; Garcia, J.; Schwarz, K.; Beretta, M.; Sandahl, T.D.; Jimenez-Rivera, C.; Kerkar, N.; Brecelj, J.; Mujawar, Q.; Rock, N.; Busoms, C.M.; Karnsakul, W.; Lurz, E.; Santos-Silva, E.; Blondet, N.; Bujanda, L.; Shah, U.; Thompson, R.J.; Hansen, B.E.; Kamath, B.M.; Global ALagille Alliance (GALA) Study Group, Koç University Hospital, School of Medicine, Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), Vandriel, S.M.; Li, L.T.; She, H.; Wang, J.S.; Gilbert, M.A.; Jankowska, I.; Czubkowski, P.; Gliwicz-Miedzi?ska, D.; Gonzales, E.M.; Jacquemin, E.; Bouligand, J.; Spinner, N.B.; Loomes, K.M.; Piccoli, D.A.; D'Antiga, L.; Nicastro, E.; Sokal, É.; Demaret, T.; Ebel, N.H.; Feinstein, J.A.; Fawaz, R.; Nastasio, S.; Lacaille, F.; Debray, D.; Arnell, H.; Fischler, B.; Siew, S.; Stormon, M.; Karpen, S.J.; Romero, R.; Kim, K.M.; Baek, W.Y.; Hardikar, W.; Shankar, S.; Roberts, A.J.; Evans, H.M.; Jensen, M.K.; Kavan, M.; Sundaram, S.S.; Chaidez, A.; Karthikeyan, P.; Sanchez, M.C.; Cavalieri, M.L.; Verkade, H.J.; Lee, W.S.; Squires, J.E.; Hajinicolaou, C.; Lertudomphonwanit, C.; Fischer, R.T.; Larson-Nath, C.; Mozer-Glassberg, Y.; Lin, H.C.; Quintero, Bernabeu J.; Alam, S.; Kelly, D.; Carvalho, E.; Ferreira, C.T.; Indolfi, G.; Quiros-Tejeira, R.E.; Bulut, P.; Calvo, P.L.; Önal, Z.; Valentino, P.L.; Desai, D.M.; Eshun, J.; Rogalidou, M.; Dezs?fi, A.; Wiecek, S.; Nebbia, G.; Borges Pinto, R.; Wolters, V.M.; Tamara, M.L.; Zizzo, A.N.; Garcia, J.; Schwarz, K.; Beretta, M.; Sandahl, T.D.; Jimenez-Rivera, C.; Kerkar, N.; Brecelj, J.; Mujawar, Q.; Rock, N.; Busoms, C.M.; Karnsakul, W.; Lurz, E.; Santos-Silva, E.; Blondet, N.; Bujanda, L.; Shah, U.; Thompson, R.J.; Hansen, B.E.; Kamath, B.M.; Global ALagille Alliance (GALA) Study Group, Koç University Hospital, and School of Medicine
- Abstract
Background and aims: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real-world data are lacking. This study aimed to elucidate the natural history of liver disease in a contemporary, international cohort of children with ALGS. Approach and results: This was a multicenter retrospective study of children with a clinically and/or genetically confirmed ALGS diagnosis, born between January 1997 and August 2019. Native liver survival (NLS) and event-free survival rates were assessed. Cox models were constructed to identify early biochemical predictors of clinically evident portal hypertension (CEPH) and NLS. In total, 1433 children (57% male) from 67 centers in 29 countries were included. The 10 and 18-year NLS rates were 54.4% and 40.3%. By 10 and 18 years, 51.5% and 66.0% of children with ALGS experienced >= 1 adverse liver-related event (CEPH, transplant, or death). Children (>6 and <= 12 months) with median total bilirubin (TB) levels between >= 5.0 and <10.0 mg/dl had a 4.1-fold (95% confidence interval [CI], 1.6-10.8), and those >= 10.0 mg/dl had an 8.0-fold (95% CI, 3.4-18.4) increased risk of developing CEPH compared with those 10.0 mg/dl were associated with a 4.8 (95% CI, 2.4-9.7) and 15.6 (95% CI, 8.7-28.2) increased risk of transplantation relative to <5.0 mg/dl. Median TB <5.0 mg/dl were associated with higher NLS rates relative to >= 5.0 mg/dl, with 79% reaching adulthood with native liver (p < 0.001). Conclusions: in this large international cohort of ALGS, only 40.3% of children reach adulthood with their native liver. A TB <5.0 mg/dl between 6 and 12 months of age is associated with better hepatic outcomes. These thresholds provide clinicians with an objective tool to assist with clinical decision-making and in the evaluation of therapies., This study received funding support from the following agencies: The Alagille Syndrome Alliance, Mirum Pharmaceuticals Inc. and Albireo Pharma, Inc. who provided unrestricted educational grants to the Hospital for Sick Children (SickKids Foundation). The study sponsors were not involved in the conduct of the research study or preparation of the manuscript.
- Published
- 2022
21. Greffe et risque allergique ; modalités de prise en charge de l’allergie alimentaire après transplantation hépatique chez l’enfant
- Author
-
Decline, J.L., Cohen, J., Gonzales, E., Taoufik, Y., and Jacquemin, E.
- Published
- 2017
- Full Text
- View/download PDF
22. Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study.
- Author
-
Kelly, D.A., Kamath, B.M., Gonzales, E., Murray, K.F., Leung, D.H., Mogul, D.B., Soglian, A., Garner, W., Vig, P., and Jacquemin, E.
- Abstract
Maralixibat, an ileal bile acid transport inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS) ≥2 months of age in Europe. Improvements in pruritus, serum bile acids (sBA), and height have been demonstrated from prior clinical trials including ICONIC, which followed participants up to 4 years, as well as IMAGO/IMAGINE and ITCH/IMAGINE-II, which reported outcomes to approximately 1.5 years. Participants from ICONIC, IMAGINE, and IMAGINE-II trials were invited to enroll in MERGE for additional long-term follow-up (LTFU); prior long-term survival outcomes (e.g., liver transplant, death) for this group have been previously reported. Here we report on efficacy in participants with additional LTFU from MERGE, including some participants that have received treatment for 7 years. All participants from ICONIC, IMAGINE and IMAGINE-II were included in the analysis. Impact of maralixibat was assessed for pruritus [ItchRO(Obs) 0-4 scale, with a ≥1-point reduction considered clinically meaningful], sBA, height and weight z-scores, ALT, total bilirubin (TB) and direct bilirubin (DB). Change from Baseline (CFB) was determined by comparing median (Q1, Q3) values from enrolment in the initial trial (i.e., ICONIC, IMAGO, or ITCH) to data from the visit in MERGE that best aligned with an annual visit. Data were analyzed for 86 participants at Baseline, with follow-up to 1 year for 76 participants, 4 years for 42 participants, and 7 years for 23 participants. Of the 86 participants, 84 had a genetic diagnosis of ALGS via the JAG1 mutation, 2 participants had a genetic diagnosis of ALGS via the NOTCH2 mutation, and 1 participant had an unidentified mutation. Baseline mean (SD) ItchRO(Obs) was 2.65 (0.75) and clinically meaningful reductions over time with CFB of -1.57 (-0.83, -2.14), -2.00 (-1.43, -2.56), and -2.14 (-1.43, -3.00) at 1 year, 4 years and 7 years, respectively. Likewise, Baseline sBA was 254 (207) µmol/L and decreased with CFB of -57 (8, -150) µmol/L, -62 (-32, -152) µmol/L, and -105 (-41, -266) µmol/L at 1 year, 4 years and 7 years. Improvement was observed in height, with Baseline z-score of -1.7 (1.27) and CFB of 0.1 (-0.1, 0.3), 0.3 (0.0, 1.0), and 0.7 (0.0, 1.2) at 1 year, 4 years and 7 years while weight z-scores were largely unchanged. Reductions in TB and DB were observed after treatment with maralixibat. No clinically meaningful changes in ALT or AST were observed with maralixibat treatment. There were no new safety signals. In this unmatched cohort, the benefit of maralixibat in ALGS patients, including both improvements in clinical outcomes and sBA, persist through 7 years of treatment. No new safety concerns were identified in the long-term. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF
23. CHARACTERIZATION OF HUMORAL REJECTION IN LIVER PEDIATRIC TRANSPLANTATION: 78
- Author
-
Dao, M., Habès, D., Mussini, C., Gonzales, E., Suberbielle, C., Jacquemin, E., Charron, D., and Guettier, C.
- Published
- 2015
24. Facteurs de risque de l’allergie alimentaire IgE médiée dans une cohorte pédiatrique avant et après transplantation hépatique
- Author
-
Guiddir, T., primary, Krzrysiek, R., additional, Billard, C., additional, Kyheng, C., additional, Cohen, J., additional, Ackermann, O., additional, Jacquemin, E., additional, and Nemni, A., additional
- Published
- 2021
- Full Text
- View/download PDF
25. Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency
- Author
-
Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), van Wessel, D. B. E.; Thompson, R. J.; Gonzales, E.; Jankowska, I.; Shneider, B. L.; Sokal, E.; Grammatikopoulos, T.; Kadaristiana, A.; Jacquemin, E.; Spraul, A.; Lipiński, P.; Czubkowski, P.; Rock, N.; Shagrani, M.; Broering, D.; Algoufi, T.; Mazhar, N.; Nicastro, E.; Kelly, D.; Nebbia, G.; Arnell, H.; Fischler, B.; Hulscher, J. B. F.; Serranti, D.; Debray, D.; Lacaille, F.; Goncalves, C.; Hierro, L.; Muñoz Bartolo, G.; Mozer-Glassberg, Y.; Azaz, A.; Brecelj, J.; Dezsőfi, A.; Luigi Calvo, P.; Krebs-Schmitt, D.; Hartleif, S.; van der Woerd, W. L.; Wang, J. S.; Li, L. T.; Durmaz, Ö.; Kerkar, N.; Hørby Jørgensen, M.; Fischer, R.; Jimenez-Rivera, C.; Alam, S.; Cananzi, M.; Laverdure, N.; Ferreira, C. T.; Ordonez, F.; Wang, H.; Sency, V.; Kim, K. M.; Chen, H. L.; Carvalho, E.; Fabre, A.; Quintero Bernabeu, J.; Alonso, E. M.; Sokol, R. J.; Suchy, F. J.; Loomes, K. M.; McKiernan, P. J.; Rosenthal, P.; Turmelle, Y.; Rao, G. S.; Horslen, S.; Kamath, B. M.; Rogalidou, M.; Karnsakul, W. W.; Hansen, B.; Verkade, H. J., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine, Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), van Wessel, D. B. E.; Thompson, R. J.; Gonzales, E.; Jankowska, I.; Shneider, B. L.; Sokal, E.; Grammatikopoulos, T.; Kadaristiana, A.; Jacquemin, E.; Spraul, A.; Lipiński, P.; Czubkowski, P.; Rock, N.; Shagrani, M.; Broering, D.; Algoufi, T.; Mazhar, N.; Nicastro, E.; Kelly, D.; Nebbia, G.; Arnell, H.; Fischler, B.; Hulscher, J. B. F.; Serranti, D.; Debray, D.; Lacaille, F.; Goncalves, C.; Hierro, L.; Muñoz Bartolo, G.; Mozer-Glassberg, Y.; Azaz, A.; Brecelj, J.; Dezsőfi, A.; Luigi Calvo, P.; Krebs-Schmitt, D.; Hartleif, S.; van der Woerd, W. L.; Wang, J. S.; Li, L. T.; Durmaz, Ö.; Kerkar, N.; Hørby Jørgensen, M.; Fischer, R.; Jimenez-Rivera, C.; Alam, S.; Cananzi, M.; Laverdure, N.; Ferreira, C. T.; Ordonez, F.; Wang, H.; Sency, V.; Kim, K. M.; Chen, H. L.; Carvalho, E.; Fabre, A.; Quintero Bernabeu, J.; Alonso, E. M.; Sokol, R. J.; Suchy, F. J.; Loomes, K. M.; McKiernan, P. J.; Rosenthal, P.; Turmelle, Y.; Rao, G. S.; Horslen, S.; Kamath, B. M.; Rogalidou, M.; Karnsakul, W. W.; Hansen, B.; Verkade, H. J., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine
- Abstract
University of Colorado; Baylor College of Medicine; Children’s Hospital of Philadelphia; Children’s Hospital of Pittsburgh; St Louis Children’s Hospital; Riley Hospital for Children; Seattle Children’s Hospital; M.D./Ph.D. Scholarship from the University of Groningen; European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Networking Grant 2019; ChilDReN National Institutes of Health Grants; Ann & Robert H. Lurie Children’s Hospital; Albireo and Mirum Pharmaceuticals
- Published
- 2021
26. Colestasis neonatales
- Author
-
Gonzales, E. and Jacquemin, E.
- Published
- 2007
- Full Text
- View/download PDF
27. Dépistage de l'atrésie des voies biliaires et couleur des selles : méthode de l'échelle colorimétrique
- Author
-
Jacquemin, E.
- Published
- 2007
- Full Text
- View/download PDF
28. Facteurs de risque et évolution des allergies alimentaires IgE médiées avant et après transplantation hépatique dans une cohorte pédiatrique française
- Author
-
Guiddir, T., primary, Kzrysiek, R., additional, Kyheng, C., additional, Billard-Larue, C., additional, Cohen, J., additional, Ackermann, O., additional, Jacquemin, E., additional, and Nemni, A., additional
- Published
- 2021
- Full Text
- View/download PDF
29. Les indications actuelles de l’endoscopie digestive pédiatrique
- Author
-
Mougenot, J. -F., Faure, Ch., Olives, J. -P., Chouraqui, J. -P., Codoner, P., Gottrand, F., Jacquemin, E., Lenaerts, C., Maherzi, A., Morali, A., Mouterde, O., Roy, P., Sarles, J., Scaillon, M., Tounian, P., and le groupe de lecture du GFHGNP
- Published
- 2002
- Full Text
- View/download PDF
30. Congenital Portosystemic Shunts in Children: Recognition, Evaluation, and Management
- Author
-
Bernard, O., Franchi-Abella, S., Branchereau, S., Pariente, D., Gauthier, F., and Jacquemin, E.
- Published
- 2012
31. Low-Frequency Drone-Borne GPR for Soil Conductivity Mapping
- Author
-
Wu, K., primary, Jacquemin, E., additional, Palt, L., additional, Ory, L., additional, Parizel, T., additional, Dienst, V. Vincent, additional, and Lambot, S., additional
- Published
- 2021
- Full Text
- View/download PDF
32. Facteurs de risque de l’allergie alimentaire IgE médiée dans une cohorte pédiatrique avant et après transplantation hépatique
- Author
-
Guiddir, T., primary, Kzrysiek, R., additional, Billard, C., additional, Kyheng, C., additional, Cohen, J., additional, Ackermann, O., additional, Jacquemin, E., additional, and Nemni, A., additional
- Published
- 2020
- Full Text
- View/download PDF
33. Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis
- Author
-
Jacquemin, E., Hermeziu, B., Kibleur, Y., Friteau, I., Mathieu, D., Le Coz, F., Moyse, D., Gérardin, M., Jacqz-Aigrain, E., and Munck, A.
- Published
- 2009
- Full Text
- View/download PDF
34. Maralixibat-treated patients with Alagille syndrome (ALGS) demonstrate improved event-free survival in a natural history comparison with patients from the GALA database: application of real-world evidence analytics.
- Author
-
Hansen, B. E., Vandriel, S. M., Vig, P., Garner, W., Li, L.-T., She, H., Wang, J.-S., Gilbert, M. A., Jankowska, I., Czubkowski, P., Gliwicz-Miedzińska, D., Gonzales, E. M., Jacquemin, E., Bouligand, J., Spinner, N. B., Loomes, K. M., Piccoli, D. A., D'Antiga, L., Nicastro, E., and Sokal, É.
- Published
- 2022
- Full Text
- View/download PDF
35. Acute vanishing bile duct syndrome after ibuprofen therapy in a child
- Author
-
Taghian, M., Tran, T.A., Bresson-Hadni, S., Menget, A., Felix, S., and Jacquemin, E.
- Published
- 2004
- Full Text
- View/download PDF
36. Liver dysfunction and acute cardiocirculatory failure in children
- Author
-
Jacquemin, E., Saliba, E., Blond, M. H., Chantepie, A., and Laugier, J.
- Published
- 1992
- Full Text
- View/download PDF
37. Analysis of opsin mRNA and protein expression in adult and regenerating newt retina by immunology and hybridization
- Author
-
Bugra, K., Jacquemin, E., Ortiz, J. R., Jeanny, J. C., and Hicks, D.
- Published
- 1992
- Full Text
- View/download PDF
38. Expression of sodium-independent organic anion uptake systems of skate liver in Xenopus laevis oocytes
- Author
-
Jacquemin, E., Hagenbuch, B., Wolkoff, A.W., Meier, P.J., and Boyer, J.L.
- Subjects
Xenopus -- Research ,Oocytes -- Analysis ,Liver -- Physiological aspects ,Biological sciences - Abstract
A study of Xenopus laevis oocytes administered with total skate liver mRNA reveals the expression of sodium-independent and chloride-dependent sulfobromophthalein (BSP) and taurocholate uptake. Two different transport systems mediate the sodium-independent taurocholate uptake in skate liver. The organic anion transport system for chloride-dependent BSP uptake is expressed in the liver of lower vertebrates, representing a phylogenetically old system.
- Published
- 1995
39. LONG TERM FOLLOW-UP OF CHILDREN RECEIVING TACROLIMUS OR CICLOSPORIN A-MICROEMULSION POST LIVER TRANSPLANTATION
- Author
-
Lloyd, C, Arshad, A, Jara, P, Burdelski, M, Becker, M, Gridelli, B, Boillot, O, Manzanares, J, Colledan, M, Jacquemin, E, Reding, R, Kelly, D, Lloyd C, Arshad A, Jara P, Burdelski M, Becker M, Gridelli B, Boillot O, Manzanares J, Colledan M, Jacquemin E, Reding R, Kelly D, Lloyd, C, Arshad, A, Jara, P, Burdelski, M, Becker, M, Gridelli, B, Boillot, O, Manzanares, J, Colledan, M, Jacquemin, E, Reding, R, Kelly, D, Lloyd C, Arshad A, Jara P, Burdelski M, Becker M, Gridelli B, Boillot O, Manzanares J, Colledan M, Jacquemin E, Reding R, and Kelly D
- Published
- 2017
40. 68 - Hépatites virales
- Author
-
Ackermann, O., Thébaut, A., Jacquemin, E., and Gonzalès, E.
- Published
- 2018
- Full Text
- View/download PDF
41. 9 - Ictères de l’enfant
- Author
-
Gonzalès, E., Habes, D., Hermeziu, B., and Jacquemin, E.
- Published
- 2018
- Full Text
- View/download PDF
42. Transplantation/Digestive tract
- Author
-
Durand, P., Jacquemin, E., Chardot, C., Iserin, F., Dousset, B., Devictor, D., Weiss, Irwin, Erian, Cherif, Ament, Marvin, Vargas, Jorge, McDiarmid, Sue, Brill, Judith, Le Pommelet, C., Debray, D., Sasbón J., Centeno M., Entin E., Acerenza M., Ciocca M., Goñi J., Bianco G., Weller G., Imventarza O., Ruza F., Calvo C., Dorao P. G., Filgueiras D., Alvarez E., Delgado M. A., Flores, J. Casado, Mora, E., García Teresa M. A., Azagra, A. Martínez, Serrano, A., Ibiza E., Abengochea A., Modesto V., Abengochea B., Arago J., Sanchis R., Varas R., Garcia E., Booker P. D., Prosser D. P., Franks R., Phuong, Kiel Dang, and Thanh, Hai Le
- Published
- 1996
- Full Text
- View/download PDF
43. Classical osseous lesions leading to an unsuspected diagnosis
- Author
-
Almes, M., Fayard, C., Gonzales, E., Hermeziu, B., Bellesme, C., Jacquemin, E., Koné-Paut, I., Adamsbaum, C., and Dusser, P.
- Published
- 2017
- Full Text
- View/download PDF
44. Unusual osseous presentation of Wilson disease in a child
- Author
-
Almes, M., Fayard, C., Gonzales, E., Hermeziu, B., Bellesme, C., Jacquemin, E., Koné-Paut, I., Adamsbaum, C., and Dusser, P.
- Published
- 2017
- Full Text
- View/download PDF
45. LONG TERM FOLLOW-UP OF CHILDREN RECEIVING TACROLIMUS OR CICLOSPORIN A-MICROEMULSION POST LIVER TRANSPLANTATION
- Author
-
Lloyd C, Arshad A, Jara P, Burdelski M, Becker M, Gridelli B, Boillot O, Manzanares J, Colledan M, Jacquemin E, Reding R, Kelly D, Lloyd, C, Arshad, A, Jara, P, Burdelski, M, Becker, M, Gridelli, B, Boillot, O, Manzanares, J, Colledan, M, Jacquemin, E, Reding, R, and Kelly, D
- Subjects
LIVER TRANSPLANTATION - Published
- 2017
46. Les cholestases néonatales : diagnostic et étiologie
- Author
-
Jacquemin, E.
- Published
- 2001
- Full Text
- View/download PDF
47. Chapitre 16 - Allergies alimentaires et transplantations
- Author
-
Decline, J.-L., Cohen, J., Taoufik, Y., and Jacquemin, E.
- Published
- 2017
- Full Text
- View/download PDF
48. Long-term outcome of liver transplantation in childhood: A study of 20-year survivors
- Author
-
Martinelli, J., primary, Habes, D., additional, Majed, L., additional, Guettier, C., additional, Gonzalès, E., additional, Linglart, A., additional, Larue, C., additional, Furlan, V., additional, Pariente, D., additional, Baujard, C., additional, Branchereau, S., additional, Gauthier, F., additional, Jacquemin, E., additional, and Bernard, O., additional
- Published
- 2018
- Full Text
- View/download PDF
49. The natural course of FIC1 deficiency and BSEP deficiency: Initial results from the NAPPED-consortium (Natural course and Prognosis of PFIC and Effect of biliary Diversion)
- Author
-
van Wessel, D., primary, Thompson, R., additional, Grammatikopoulos, T., additional, Kadaristiana, A., additional, Jankowska, I., additional, Lipiński, P., additional, Czubkowski, P., additional, Gonzales, E., additional, Jacquemin, E., additional, Spraul, A., additional, Sokal, E., additional, Shagrani, M.A., additional, Broering, D.C., additional, Algoufi, T., additional, Mazhar, N., additional, Nicastro, E., additional, Kelly, D., additional, Nebbia, G., additional, Arnell, H., additional, Fischler, B., additional, Sankaranarayanan, S., additional, Hulscher, J., additional, Serranti, D., additional, Arikan, C., additional, Polat, E., additional, Debray, D., additional, Lacaille, F., additional, Goncalves, C., additional, Hierro, L., additional, Bartolo, G.M., additional, Mozer-Glassberg, Y., additional, Azaz, A., additional, Brecelj, J., additional, Dezsőfi, A., additional, Calvo, P.L., additional, Pizzol, A., additional, Schmitt, D., additional, Sturm, E., additional, van der Woerd, W., additional, Hansen, B., additional, and Verkade, H., additional
- Published
- 2018
- Full Text
- View/download PDF
50. Clinical presentation and outcome of Wilson’s disease patients in a monocentric cohort of liver reference center
- Author
-
Sobesky, R., primary, Darce, M., additional, Agostini, H., additional, Fernandez, I., additional, Usardi, A., additional, Adam, R., additional, Cherqui, D., additional, Gonzales, E., additional, Jacquemin, E., additional, Samuel, D., additional, Poujois, A., additional, Woimant, F., additional, and Duclos-Vallée, J.-C., additional
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.